Nom du produit:3,5-Dimethoxyaniline

IUPAC Name:3,5-dimethoxyaniline

CAS:10272-07-8
Formule moléculaire:C8H11NO2
Pureté:95%+
Numéro de catalogue:CM118173
Poids moléculaire:153.18

Unité d'emballage Stock disponible Prix($) Quantité
CM118173-100g in stock ƱǕǕ
CM118173-500g in stock Ȍƻɐ

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:10272-07-8
Formule moléculaire:C8H11NO2
Point de fusion:-
Code SMILES:NC1=CC(OC)=CC(OC)=C1
Densité:
Numéro de catalogue:CM118173
Poids moléculaire:153.18
Point d'ébullition:178°C at 760 mmHg
N° Mdl:MFCD00008392
Stockage:Keep in dark place, store at 2-8°C.

Category Infos

Benzenes
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

Column Infos

Nitrogen Compounds
Nitrogen compounds can be classified as mineral or organic. Mineral compounds are essentially formed by the ammonium ion (NH4+), which is generated when ammonium salts are dissolved in water. Organic compounds, in contrast, are carbon and hydrogen compounds that contain a nitrogen atom. All organic nitrogen-containing compounds can be considered as derivatives of ammonia in which one or more hydrogen atoms are substituted by hydrocarbon radicals.
Erdafitinib
The Janssen Pharmaceutical Companies of Johnson & Johnson announced on September 8, 2023, that it had submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) to seek approval of Erdafitinib for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor 3 (FGFR3) genetic alterations, with disease progression during or following at least one line of therapy containing a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-[L]1) inhibitor.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.